Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus MEDLINE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Breast cancer surveillance in BRCA positive Sri Lankan women: health equity for a high-risk group at a limited resource setting.

Title: Breast cancer surveillance in BRCA positive Sri Lankan women: health equity for a high-risk group at a limited resource setting.
Authors: Liyanage UA; Department of Anatomy, Genetics and Biomedical Informatics, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka. udari@anat.cmb.ac.lk.; Sirisena ND; Department of Anatomy, Genetics and Biomedical Informatics, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka.; Deshapriya PC; Department of Anatomy, Genetics and Biomedical Informatics, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka.; Dissanayake VHW; Department of Anatomy, Genetics and Biomedical Informatics, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka.
Source: BMC women's health [BMC Womens Health] 2023 Nov 28; Vol. 23 (1), pp. 636. Date of Electronic Publication: 2023 Nov 28.
Publication Type: Journal Article
Language: English
Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 101088690 Publication Model: Electronic Cited Medium: Internet ISSN: 1472-6874 (Electronic) Linking ISSN: 14726874 NLM ISO Abbreviation: BMC Womens Health Subsets: MEDLINE
Imprint Name(s): Original Publication: [London] : BioMed Central, 2001-
MeSH Terms: Breast Neoplasms*/diagnosis ; Breast Neoplasms*/genetics ; Breast Neoplasms*/surgery ; Health Equity*; BRCA1 Protein/genetics ; Sri Lanka/epidemiology ; BRCA2 Protein/genetics ; Male ; Humans ; Female ; Mastectomy ; Retrospective Studies ; Mutation ; Genes, BRCA1 ; Mammography ; Magnetic Resonance Imaging ; Genetic Predisposition to Disease
Abstract: Background: BRCA1 and BRCA2 pathogenic variants account for 90% of hereditary breast malignancies, incurring a lifetime breast cancer risk of 85% and 40-45% respectively, in affected individuals. Well-resourced health care settings offer genetic counselling and genetic screening for susceptible individuals, followed by intense breast cancer surveillance programmes for those identified at high risk of breast cancer. Such high standards of care are not available in countries with limited resources. This study assessed breast cancer surveillance behaviors among a cohort of BRCA positive Sri Lankan women.; Methods: A retrospective case review of all patients diagnosed with pathogenic variants in BRCA1 and BRCA2 genes from 2015 to 2022 at the Human Genetics Unit, Faculty of Medicine, University of Colombo was carried out followed by telephone interviews of the respondents. Patients who were not contactable, deceased, undergone bilateral mastectomy and males were excluded from the interview component of the study. Standard descriptive statistics were used to analyze the data using SPSS statistics version 25.; Results: Only 25 patients were diagnosed during the study period:14/25 women responded (6/25 deceased, 3/25 non-contactable; 2/25 excluded). 71.4% (10/14) had performed breast self-examination during the preceding month; 35.7% (5/14) had a clinical breast examination (CBE), and 50% (7/14) had undergone a screening/diagnostic mammogram during the last one year. 28.5% (4/14) had undergone both mammography and CBE; 21.45% (3/14) mammogram only, 7.1% (1/14) had CBE only. 42.8%(6/14) had not undergone any surveillance(mammography, CBE or MRI). None had dual screening with mammogram and MRI. 85.71% (12/14) women expressed willingness to participate in a regular screening programme if made available.; Conclusion: Fifty percent of BRCA1/2 positive women in our study had not undergone annual imaging-based surveillance by mammography or MRI, and none had undergone annual dual screening with mammography and MRI, indicating inadequate breast cancer surveillance in this high-risk group.; (© 2023. The Author(s).)
References: Breast J. 2009 Jan-Feb;15(1):4-16. (PMID: 19141130); Breast Care (Basel). 2008;3(1):21-27. (PMID: 20824016); BMC Cancer. 2018 Apr 27;18(1):482. (PMID: 29703165); Breast. 2014 Aug;23(4):482-8. (PMID: 24821458); Hered Cancer Clin Pract. 2017 Jul 26;15:11. (PMID: 28770017); J Am Coll Radiol. 2018 Mar;15(3 Pt A):408-414. (PMID: 29371086); BMJ. 2014 Apr 28;348:g2756. (PMID: 24778341); Cancers (Basel). 2022 Aug 30;14(17):. (PMID: 36077752); J Natl Compr Canc Netw. 2021 Jan 06;19(1):77-102. (PMID: 33406487); BMJ. 2021 Feb 24;372:n256. (PMID: 33627312); J BUON. 2018 Jul-Aug;23(4):862-866. (PMID: 30358186); Mol Genet Genomic Med. 2019 Jun;7(6):e744. (PMID: 31106988); Am J Public Health. 2016 Oct;106(10):1842-8. (PMID: 27552275); Breast. 2022 Aug;64:85-99. (PMID: 35636342)
Contributed Indexing: Keywords: Breast cancer risk; Cancer genetic screening; Hereditary breast cancer; Screening mammography; South Asia
Substance Nomenclature: 0 (BRCA1 protein, human); 0 (BRCA1 Protein); 0 (BRCA2 protein, human); 0 (BRCA2 Protein)
Entry Date(s): Date Created: 20231129 Date Completed: 20231130 Latest Revision: 20240117
Update Code: 20260130
PubMed Central ID: PMC10685476
DOI: 10.1186/s12905-023-02797-z
PMID: 38017478
Database: MEDLINE

Journal Article